RxDoctor Payments DataLook up a doctor →

Ruwani Gunawardane, MD

Neurology · Fulton, MDNPI 1093780728

Payments from drug & device makers

$478,613in general payments, 2019–2025

Across 3,489 payments — averaging $137.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$374K
  • Biohaven Pharmaceutical Holding Company Ltd.$27K
  • Biohaven Pharmaceuticals, Inc.$13K
  • Kyowa Kirin, Inc.$9K
  • Promius Pharma LLC$5K
  • Biogen$4K
  • plus $46K from 54 others

What the payments were for

  • Consulting fees$7,0351%
  • Speaking & faculty fees$339,29771%
  • Travel & lodging$66,56314%
  • Food & beverage$65,27914%
  • Education$4390%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)1,201$373,936
Biohaven Pharmaceutical Holding Company Ltd.74$27,194
Biohaven Pharmaceuticals, Inc.59$13,166
Kyowa Kirin, Inc.63$8,626
Promius Pharma LLC14$4,605
Biogen220$4,214
Akcea Therapeutics, Inc.21$3,734
Amgen(2 entities)110$3,398
Eisai Inc.54$3,247
Teva Pharmaceuticals USA, Inc.106$3,044
Currax Pharmaceuticals LLC91$2,169
Pfizer116$1,989
UCB, Inc.97$1,940
Lundbeck LLC82$1,723
Lilly USA, LLC60$1,658
Amneal Pharmaceuticals LLC57$1,534
Genentech USA, Inc.63$1,522
Neurelis, Inc.51$1,279
Bristol Myers Squibb61$1,219
Sunovion Pharmaceuticals Inc.79$1,155
ANI Pharmaceuticals, Inc.47$1,146
Argenx US, Inc.47$1,059
Bausch Health US, LLC87$1,021
AstraZeneca33$1,010
Neurocrine Biosciences, Inc.27$1,009
Johnson & Johnson81$882
CSL Behring34$827
Noctrix Health, Inc.3$736
Axsome Therapeutics, Inc.26$722
Vanda Pharmaceuticals Inc.17$605
Grifols USA, LLC29$571
Arbor Pharmaceuticals, Inc.37$517
TG Therapeutics, Inc.17$497
Scilex Pharmaceuticals Inc.20$496
Catalyst Pharmaceuticals, Inc.20$403
Impel Pharmaceuticals Inc.17$397
Takeda Pharmaceuticals U.S.A., Inc.20$387
Sumitomo Pharma America, Inc.20$336
Upsher-smith Laboratories LLC19$306
Mallinckrodt Hospital Products Inc.17$300
Adamas Pharmaceuticals, Inc.20$273
Avanir Pharmaceuticals, Inc.14$254
E.r. Squibb & Sons, L.L.C.10$253
Collegium Pharmaceutical, Inc.16$251
Alnylam Pharmaceuticals Inc.8$201
Livanova USA, Inc.9$191
Avion Pharmaceuticals17$186
Acorda Therapeutics, Inc9$183
Azurity Pharmaceuticals, Inc.8$176
Supernus Pharmaceuticals, Inc.8$150
MDD US Operations, LLC1$150
Acadia Pharmaceuticals Inc5$142
EMD Serono, Inc.2$133
Jazz Pharmaceuticals Inc.6$128
Sanofi5$124
4web, Inc.1$114
Vertical Pharmaceuticals, LLC7$106
GE HealthCare4$105
Otsuka America Pharmaceutical, Inc.4$86
Bayer3$68

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$478,613 in reported general payments places this provider in the 90th percentile of 442 neurology providers in Maryland.

See all neurology providers in Maryland

Medicare billing

Part B allowed, 2024
$340,374
Medicare patients
485
Services billed
8,322

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Austedo XrDeutetrabenazine27$177,306
TysabriNatalizumab20$173,689
Nurtec OdtRimegepant Sulfate26$50,482
UbrelvyUbrogepant26$41,349
BotoxOnabotulinumtoxina20$25,901
Rivastigmine102$25,366
Ajovy AutoinjectorFremanezumab-Vfrm15$21,659
RytaryCarbidopa/Levodopa17$20,020
FycompaPerampanel11$16,685
Memantine Hcl491$15,516
Doxepin Hcl50$14,240
ValtocoDiazepam16$13,921
Emgality PenGalcanezumab-Gnlm12$8,088
Gabapentin222$5,228
Lidocaine32$4,341

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo Xr$3,044$177,30627 claims
BiogenTysabri$4,214$173,68920 claims
AbbVieUbrelvy, Botox$373,936$67,25046 claims
PfizerNurtec Odt$1,989$50,48226 claims
Amneal Pharmaceuticals LLCRytary$1,534$20,02017 claims
Eisai Inc.Fycompa$3,247$16,68511 claims
Neurelis, Inc.Valtoco$1,279$13,92116 claims
Upsher-smith Laboratories LLCTopiramate$306$57120 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 442 neurology providers in Maryland.

Other neurology in Fulton

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →